Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betsy Hirsch

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyLeslie Mortland, Todd A Alonzo, Roland B Walter, et al.
Archives of Pathology & Laboratory Medicine|August 21, 2019
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431Kelley J Mast, Jeffrey W Taub, Todd A Alonzo, et al.
Blood|April 9, 2017
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trialJeffrey W Taub, Jason N Berman, Johann K Hitzler, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Blood|July 28, 2021
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trialJohann Hitzler, Todd Alonzo, Robert Gerbing, et al.
Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2025
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Blood Advances|February 2, 2024
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemiaOussama Abla, Rhonda E Ries, Tim Triche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyLeslie Mortland, Todd A Alonzo, Roland B Walter, et al.
Archives of Pathology & Laboratory Medicine|August 21, 2019
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431Kelley J Mast, Jeffrey W Taub, Todd A Alonzo, et al.
Blood|April 9, 2017
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trialJeffrey W Taub, Jason N Berman, Johann K Hitzler, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Blood|July 28, 2021
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trialJohann Hitzler, Todd Alonzo, Robert Gerbing, et al.
Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2025
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Pageof 7